Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
UB-923 is a preclinical-stage afucosylated monoclonal antibody developed by United BioPharma (UBP) that targets the CD20 antigen. CD20 is a protein expressed on the surface of B cells and is a well-validated target for the treatment of B-cell malignancies. By utilizing afucosylation technology, UB-923 is engineered to have a higher affinity for the FcγRIIIa receptor on effector cells, such as natural killer (NK) cells, thereby significantly enhancing antibody-dependent cellular cytotoxicity (ADCC) compared to non-modified anti-CD20 antibodies. The drug is being developed for the treatment of various B-cell lymphoproliferative disorders, including non-Hodgkin lymphoma, chronic lymphocytic leukemia, and follicular lymphoma.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on UB-923.